Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AVIR
Nasdaq
2834
ateapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
- May 7th, 2025 11:00 am
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
- May 1st, 2025 11:00 am
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
- Apr 23rd, 2025 11:00 am
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
- Apr 17th, 2025 11:00 am
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
- Apr 9th, 2025 11:00 am
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
- Mar 26th, 2025 5:58 pm
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting
- Mar 26th, 2025 1:34 pm
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
- Mar 26th, 2025 12:00 pm
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
- Mar 21st, 2025 9:54 pm
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory
- Mar 21st, 2025 12:25 pm
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
- Mar 19th, 2025 11:00 am
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential
- Mar 13th, 2025 5:05 pm
Q4 2024 Atea Pharmaceuticals Inc Earnings Call
- Mar 7th, 2025 5:46 pm
Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ...
- Mar 7th, 2025 7:17 am
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Mar 6th, 2025 9:05 pm
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
- Feb 27th, 2025 12:00 pm
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
- Feb 24th, 2025 12:00 pm
February 2025 US Penny Stocks To Watch
- Feb 6th, 2025 5:11 pm
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 13th, 2025 12:00 pm
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2025 12:00 pm
Scroll